logo

For the Inventor, By the Inventor

Koln, Germany

Reilinde Wittka

USPTO Granted Patents = 17

Average Co-Inventor Count = 7.9

ph-index = 3

Forward Citations = 48(Granted Patents)


Location History:

  • Koln, DE (1996 - 2000)
  • Köln, DE (2001)

Company Filing History:

goldMedal17 out of 12,160 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1996-2001

Loading Chart...
17 patents (USPTO):Explore Patents
1. 6194428 - Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system (2001-02-27),
2. 6147087 - Use of 1,2-Bridged 1,4-dihydropyridines as medicaments (2000-11-14),
3. 6121284 - 2,3-bridged 1,4-dihydropyridines, and their use as medicaments (2000-09-19),
4. 5990121 - Use of 1,2-bridged 1,4-dihydropyridines as medicaments (1999-11-23),
5. 5955482 - Use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments (1999-09-21),
6. 5942526 - 5-acyl-1,4-dihydropyridines (1999-08-24),
7. 5874462 - Use of substituted 6-amino-4H-pyrans (1999-02-23),
8. 5861394 - Use of N-substituted phenothiazines (1999-01-19),
9. 5760073 - Substituted 4H-pyrans (1998-06-02),
10. 5756515 - Dioxo-thiopyrano-pyridine-carboxylic acid derivatives and their use as (1998-05-26),
11. 5719181 - Use of acyl-substituted aminopyrans (1998-02-17),
12. 5670525 - Substituted 4-phenyl-6-amino-nicotinic acid compounds useful in the (1997-09-23),
13. 5665741 - 1,4-dihydropyridine-3,5-dicarboxylic acid esters in treatment of (1997-09-09),
14. 5652264 - Cyclohexadiene derivatives useful in the treatment of depression (1997-07-29),
15. 5652251 - 6-amino-1,4-dihydropyridine compounds as medicaments for treatment of (1997-07-29),

Title: Reilinde Wittka: Pioneering Innovator in the Field of Medicinal Treatments

Introduction:

Reilinde Wittka, a distinguished inventor based in Koln, Germany, has made significant contributions to the field of medicinal treatments through his groundbreaking patents and unwavering commitment to excellence. With a total of 17 patents to his name, Wittka's innovative solutions have paved the way for novel therapies in treating diseases of the central nervous system.

Latest Patents:

Wittka's recent patents include the groundbreaking inventions focusing on the use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating cerebral disorders. Additionally, his work on the utilization of 1,2-Bridged 1,4-dihydropyridines as medicaments demonstrates his profound understanding of selective potassium channel modulation for central nervous system treatment.

Career Highlights:

Currently affiliated with Bayer Aktiengesellschaft, Wittka continues to push the boundaries of technology in the pharmaceutical industry. His expertise and dedication to advancing medicinal treatments have earned him a reputation as a trailblazer in the field, inspiring the next generation of inventors and innovators worldwide.

Collaborations:

Throughout his illustrious career, Wittka has collaborated with esteemed colleagues such as Klaus Urbahns and Hans-Georg Heine. Together, they have spearheaded groundbreaking research initiatives and developed innovative solutions to address complex medical challenges.

Conclusion:

Reilinde Wittka's passion for innovation and his relentless pursuit of excellence have positioned him as a driving force in the field of medicinal treatments. His exceptional contributions continue to shape the landscape of healthcare, leaving a lasting impact on the industry and inspiring future generations of inventors and innovators worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…